Kaleido Biosciences Inc

-0.13 (-3.16%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)164.99M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.12 Million
Adjusted EPS-$0.59
See more estimates
10-Day MA$4.24
50-Day MA$4.84
200-Day MA$6.75
See more pivots

Kaleido Biosciences Inc Stock, NASDAQ:KLDO

65 Hayden Avenue, Lexington, Massachusetts 02421
United States of America
Phone: +1.617.674.9000
Number of Employees: 82


Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. The firm offers microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan on January 27, 2015 and is headquartered in Lexington, MA.